Your browser doesn't support javascript.
loading
Extensive sequence and structural evolution of Arginase 2 inhibitory antibodies enabled by an unbiased approach to affinity maturation.
Chan, Denice T Y; Jenkinson, Lesley; Haynes, Stuart W; Austin, Mark; Diamandakis, Agata; Burschowsky, Daniel; Seewooruthun, Chitra; Addyman, Alexandra; Fiedler, Sebastian; Ryman, Stephanie; Whitehouse, Jessica; Slater, Louise H; Gowans, Ellen; Shibata, Yoko; Barnard, Michelle; Wilkinson, Robert W; Vaughan, Tristan J; Holt, Sarah V; Cerundolo, Vincenzo; Carr, Mark D; Groves, Maria A T.
Afiliación
  • Chan DTY; Cancer Research UK-AstraZeneca Antibody Alliance Laboratory, CB21 6GP Cambridge, United Kingdom.
  • Jenkinson L; Cancer Research UK-AstraZeneca Antibody Alliance Laboratory, CB21 6GP Cambridge, United Kingdom.
  • Haynes SW; Cancer Research UK-AstraZeneca Antibody Alliance Laboratory, CB21 6GP Cambridge, United Kingdom.
  • Austin M; Cancer Research UK-AstraZeneca Antibody Alliance Laboratory, CB21 6GP Cambridge, United Kingdom.
  • Diamandakis A; Antibody Discovery & Protein Engineering, BioPharmaceuticals Research & Development, AstraZeneca, CB21 6GH Cambridge, United Kingdom.
  • Burschowsky D; Cancer Research UK-AstraZeneca Antibody Alliance Laboratory, CB21 6GP Cambridge, United Kingdom.
  • Seewooruthun C; Leicester Institute of Structural and Chemical Biology, University of Leicester, LE1 7HB Leicester, United Kingdom.
  • Addyman A; Department of Molecular and Cell Biology, University of Leicester, LE1 7HB Leicester, United Kingdom.
  • Fiedler S; Leicester Institute of Structural and Chemical Biology, University of Leicester, LE1 7HB Leicester, United Kingdom.
  • Ryman S; Department of Molecular and Cell Biology, University of Leicester, LE1 7HB Leicester, United Kingdom.
  • Whitehouse J; Cancer Research UK-AstraZeneca Antibody Alliance Laboratory, CB21 6GP Cambridge, United Kingdom.
  • Slater LH; Cancer Research UK-AstraZeneca Antibody Alliance Laboratory, CB21 6GP Cambridge, United Kingdom.
  • Gowans E; Cancer Research UK-AstraZeneca Antibody Alliance Laboratory, CB21 6GP Cambridge, United Kingdom.
  • Shibata Y; Cancer Research UK-AstraZeneca Antibody Alliance Laboratory, CB21 6GP Cambridge, United Kingdom.
  • Barnard M; Cancer Research UK-AstraZeneca Antibody Alliance Laboratory, CB21 6GP Cambridge, United Kingdom.
  • Wilkinson RW; Cancer Research UK-AstraZeneca Antibody Alliance Laboratory, CB21 6GP Cambridge, United Kingdom.
  • Vaughan TJ; Cancer Research UK-AstraZeneca Antibody Alliance Laboratory, CB21 6GP Cambridge, United Kingdom.
  • Holt SV; Cancer Research UK-AstraZeneca Antibody Alliance Laboratory, CB21 6GP Cambridge, United Kingdom.
  • Cerundolo V; Early Oncology Discovery, Oncology Research & Development, AstraZeneca, CB21 6GH Cambridge, United Kingdom.
  • Carr MD; Antibody Discovery & Protein Engineering, BioPharmaceuticals Research & Development, AstraZeneca, CB21 6GH Cambridge, United Kingdom.
  • Groves MAT; Cancer Research UK-AstraZeneca Antibody Alliance Laboratory, CB21 6GP Cambridge, United Kingdom.
Proc Natl Acad Sci U S A ; 117(29): 16949-16960, 2020 07 21.
Article en En | MEDLINE | ID: mdl-32616569
Affinity maturation is a powerful technique in antibody engineering for the in vitro evolution of antigen binding interactions. Key to the success of this process is the expansion of sequence and combinatorial diversity to increase the structural repertoire from which superior binding variants may be selected. However, conventional strategies are often restrictive and only focus on small regions of the antibody at a time. In this study, we used a method that combined antibody chain shuffling and a staggered-extension process to produce unbiased libraries, which recombined beneficial mutations from all six complementarity-determining regions (CDRs) in the affinity maturation of an inhibitory antibody to Arginase 2 (ARG2). We made use of the vast display capacity of ribosome display to accommodate the sequence space required for the diverse library builds. Further diversity was introduced through pool maturation to optimize seven leads of interest simultaneously. This resulted in antibodies with substantial improvements in binding properties and inhibition potency. The extensive sequence changes resulting from this approach were translated into striking structural changes for parent and affinity-matured antibodies bound to ARG2, with a large reorientation of the binding paratope facilitating increases in contact surface and shape complementarity to the antigen. The considerable gains in therapeutic properties seen from extensive sequence and structural evolution of the parent ARG2 inhibitory antibody clearly illustrate the advantages of the unbiased approach developed, which was key to the identification of high-affinity antibodies with the desired inhibitory potency and specificity.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Arginasa / Regiones Determinantes de Complementariedad / Anticuerpos / Afinidad de Anticuerpos Límite: Humans Idioma: En Revista: Proc Natl Acad Sci U S A Año: 2020 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Arginasa / Regiones Determinantes de Complementariedad / Anticuerpos / Afinidad de Anticuerpos Límite: Humans Idioma: En Revista: Proc Natl Acad Sci U S A Año: 2020 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Estados Unidos